Elanco Animal Health Incorporated (NYSE:ELAN) Short Interest Down 18.1% in February

Elanco Animal Health Incorporated (NYSE:ELAN) was the target of a significant drop in short interest in February. As of February 27th, there was short interest totaling 15,072,733 shares, a drop of 18.1% from the February 12th total of 18,414,142 shares. Currently, 3.1% of the shares of the stock are sold short. Based on an average daily volume of 5,231,386 shares, the days-to-cover ratio is currently 2.9 days. Based on an average daily volume of 5,231,386 shares, the days-to-cover ratio is currently 2.9 days. Currently, 3.1% of the shares of the stock are sold short.

Institutional Investors Weigh In On Elanco Animal Health

A number of large investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Elanco Animal Health in the first quarter worth about $2,065,000. Goldman Sachs Group Inc. grew its holdings in shares of Elanco Animal Health by 104.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after acquiring an additional 2,445,872 shares during the period. Empowered Funds LLC raised its position in shares of Elanco Animal Health by 35.2% in the 1st quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock worth $166,000 after acquiring an additional 4,121 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Elanco Animal Health by 4.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock worth $18,830,000 after acquiring an additional 76,408 shares in the last quarter. Finally, ProShare Advisors LLC lifted its stake in shares of Elanco Animal Health by 8.7% in the 2nd quarter. ProShare Advisors LLC now owns 12,439 shares of the company’s stock valued at $178,000 after purchasing an additional 999 shares during the period. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Price Performance

NYSE ELAN traded up $0.46 on Monday, reaching $23.40. 3,818,611 shares of the company’s stock traded hands, compared to its average volume of 4,137,086. The stock has a market cap of $11.64 billion, a PE ratio of -48.76, a P/E/G ratio of 2.92 and a beta of 1.83. Elanco Animal Health has a 12 month low of $8.02 and a 12 month high of $27.72. The stock has a 50-day simple moving average of $24.53 and a 200 day simple moving average of $22.28. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.17 and a quick ratio of 1.08.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.02. The business had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.09 billion. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. The company’s revenue was up 12.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.14 earnings per share. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. As a group, research analysts predict that Elanco Animal Health will post 0.91 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. JPMorgan Chase & Co. boosted their price target on shares of Elanco Animal Health from $24.00 to $28.00 and gave the stock an “overweight” rating in a research note on Thursday, February 19th. Argus raised shares of Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a report on Wednesday, November 19th. Leerink Partners upped their target price on shares of Elanco Animal Health from $26.00 to $30.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 24th. KeyCorp increased their target price on Elanco Animal Health from $27.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Finally, Wall Street Zen upgraded Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 19th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $27.67.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.